Search clinical trials for: Inclisiran

Total 46 results

Novartis Pharmaceuticals

Not yet recruiting

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction (V-ACCELERATE)

Plaque, Atherosclerotic
Nanjing First Hospital, Nanjing Medical University

Not yet recruiting

Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques (EItoCVP)

Coronary Artery Disease
Federico II University

Recruiting

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy (CHOLINET)

Hypercholesterolemia

Italy
University of Louisville

Recruiting

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (ARTCAP)

Coronary Artery Disease | Atherosclerosis | Heart Attack

United States
Novartis Pharmaceuticals

Recruiting

Specified Drug-use Survey of Leqvio for s.c. Injection.

Hypercholesterolaemia | Familial Hypercholesterolaemia

Japan
Novartis Pharmaceuticals

Not yet recruiting

VictORION-INCLUSION is a Multicenter, Randomized, Open Label, Study of Inclisiran + Usual Care vs Usual Care Alone in an Inclusive and Underrepresented Population at High Risk for or Diagnosed With ASCVD Within a Pragmatic EHR Framework. (V-INCLUSION)

Atherosclerotic Cardiovascular Disease
Monash University
Novartis Pharmaceuticals

Recruiting

VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN) (v-ASCERTAIN)

Cerebrovascular Disease | Coronary Heart Disease (CHD) | Peripheral Arterial Disease (PAD) | Atherosclerotic Cardiovascular Disease (ASCVD)

Australia
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. (V-Mono)

Hypercholesterolemia

United States, Hungary, Mexico, Germany, Colombia
Novartis Pharmaceuticals

Recruiting

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Primary Prevention of Atherosclerotic Cardiovascular Disease

United States, China, Italy, Spain, Canada, France, Netherlands, Switzerland, Taiwan, Greece, Thailand, Brazil, India, Hungary, Latvia, Mexico, Israel, Turkey, Argentina, Singapore, Australia, Belgium, Bulgaria, Denmark, Croatia, South Africa and more
Novartis Pharmaceuticals

Recruiting

The Belgian REAL (BE.REAL) Registry (BE REAL)

Atherosclerotic Cardiovascular Disease

Belgium
Novartis Pharmaceuticals

Recruiting

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies (V-PEDS-OLE)

Heterozygous or Homozygous Familial Hypercholesterolemia

Netherlands, Israel, Hungary, Italy, Germany, Spain, France, Norway, South Africa, Turkey, United Kingdom, Canada, Switzerland, Brazil, Lebanon, Slovenia, United States, Russian Federation, Taiwan
Jena University Hospital

Not yet recruiting

Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) (GoT)

ST Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction | LDL-cholesterol

Germany
Jena University Hospital
Charite University, Berlin, Germany; Ruhr University of Bochum; Technische Universität... and other collaborators

Recruiting

German Inclisiran Network: Retrospective Registry of Patients Being Treated With the siRNA Inclisiran in Germany (GIN)

Hypercholesterolemia

Germany
Novartis Pharmaceuticals

Recruiting

Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD (VICTORION REAL)

Mixed Dyslipidemia | Primary Hypercholesterolemia

Switzerland, Saudi Arabia, United Arab Emirates, United Kingdom, Austria, Israel, China, Malaysia
Novartis Pharmaceuticals

Recruiting

A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

Hypercholesterolemia

Germany
Novartis Pharmaceuticals

Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (V-PLAQUE)

Coronary Artery Disease

United States, Italy, Spain, France, Korea, Republic of, Hungary, Japan, Argentina, China, India, Belgium, Switzerland, United Kingdom, Canada, Australia, Brazil, Chile, Ireland
Novartis Pharmaceuticals

Recruiting

Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia

China
University of Cambridge
Lund University; GE Healthcare; Cambridge University Hospitals NHS Foundation... and other collaborators

Recruiting

PET Imaging of Inflammation and Lipid Lowering Study (PIILL)

Atherosclerosis | Carotid Artery Plaque | Hypercholesterolemia | Hypercholesterolemia, Familial

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. (V-Mono China)

Primary Hypercholesterolemia or Mixed Dyslipidemia

China
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia (V-DIFFERENCE)

Hypercholesterolemia

Germany, Estonia, Spain, France, Bulgaria, Latvia, Poland, Czechia
Takeda

Active, not recruiting

A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency

Congenital Protein C Deficiency

Japan
Novartis Pharmaceuticals

Active, not recruiting

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome (V-INCEPTION)

Acute Coronary Syndrome

United States
Novartis Pharmaceuticals

Completed

Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support (SPIRIT)

Atherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein Cholesterol

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia (ORION-13)

Familial Hypercholesterolemia - Homozygous

Greece, Lebanon, Turkey, France, Canada, Malaysia, Netherlands, United States
Novartis Pharmaceuticals

Completed

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C (ORION-8)

Elevated Cholesterol | Homozygous Familial Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia | ASCVD

United States, Canada, Czechia, Denmark, Germany, Hungary, Netherlands, Poland, South Africa, Spain, Sweden, Ukraine, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Atherosclerotic Cardiovascular Disease

United States, China, South Africa, Spain, Austria, Belgium, Croatia, Estonia, Hungary, Taiwan, Turkey, Netherlands, Italy, Australia, Czechia, Denmark, France, Israel, Korea, Republic of, Thailand, Argentina, Bulgaria, Greece, Romania, Sloveni... and more
Novartis Pharmaceuticals

Active, not recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia (ORION-16)

Familial Hypercholesterolemia - Heterozygous

United States, Germany, South Africa, Greece, Italy, Czechia, Taiwan, Slovakia, Turkey, France, Russian Federation, Canada, Spain, Jordan, Switzerland, Hungary, Poland, Netherlands, Norway, United Kingdom, Lebanon, Argentina, Brazil, ... and more
Novartis Pharmaceuticals

Completed

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) (V-INITIATE)

Atherosclerotic Cardiovascular Disease

United States
LIB Therapeutics LLC
Medpace, Inc.

Active, not recruiting

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (LIBerate-VI)

Hypercholesterolemia | Atherosclerotic Ischemic Disease

Spain, Germany, France, Norway, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease (SIRIUS)

Atherosclerotic Cardiovascular Disease

France
Pauls Stradins Clinical University Hospital

Active, not recruiting

Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques

Atherosclerotic Cardiovascular Disease

Latvia
University of Oxford
Novartis Pharmaceuticals; The TIMI Study Group

Active, not recruiting

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4)

Atherosclerotic Cardiovascular Disease

United Kingdom, United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Hypercholesterolemia

China, Taiwan, Korea, Republic of, Singapore
Novartis Pharmaceuticals

Completed

Adherence and Persistence to Inclisiran Among Early Users in Germany

High Levels of Low-density Lipoprotein Cholesterol

Switzerland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-15)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia

Japan
Novartis Pharmaceuticals

Completed

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol (ORION-3)

Type2 Diabetes | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Symptomatic Atherosclerosis

Germany, United Kingdom, Netherlands, United States, Canada
Novartis Pharmaceuticals

Completed

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ORION-5)

Homozygous Familial Hypercholesterolemia

Hong Kong, Israel, Russian Federation, Serbia, South Africa, Taiwan, Turkey, Ukraine
Novartis Pharmaceuticals

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C (ORION-14)

Hyperlipidemia

China
The Medicines Company

Completed

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) (ORION-9)

Elevated Cholesterol | Heterozygous Familial Hypercholesterolemia

United States, Canada, Czechia, Denmark, Netherlands, South Africa, Spain, Sweden
The Medicines Company

Completed

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol (ORION-10)

Elevated Cholesterol | ASCVD

United States
The Medicines Company

Completed

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11)

Risk Factor, Cardiovascular | Elevated Cholesterol | ASCVD

Germany, Czechia, Hungary, Poland, South Africa, Ukraine, United Kingdom
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS); Michael J.... and other collaborators

Completed

Efficacy of Isradipine in Early Parkinson Disease

Parkinson Disease

United States, Canada
The Medicines Company

Completed

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) (ORION-1)

Diabetes | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Canada, Netherlands, United States, United Kingdom, Germany
The Medicines Company

Completed

A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Renal Impairment

New Zealand
Novartis

Completed

Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Recurrent Genital Herpes

Australia
Novartis

Completed

A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

Genital Herpes

United States

Search clinical trials for: Inclisiran

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations